ALBO Polarstern Vorraus! Für Longies und Fakten!
"On October 26, 2017, Parent entered into an asset purchase agreement pursuant to which it sold legacy intellectual property of its predecessor, Biodel,
for $4.5 million."
Optionen
| Boardmail an "t1me" |
Wertpapier: Albireo Pharma |
hier unter Seite 19....
10. Subsequent Events
On October 13, 2017, Parent entered into a sales agreement with Cowen and Company, LLC (Cowen) with respect to an at-the-market offering program under which Parent may offer and sell, from time to time at its sole discretion, up to $50 million in shares of its common stock through Cowen as its sales agent. The issuance and sale of shares under the sales agreement, if any, is subject to the effectiveness of Parents registration statement on Form S-3 that was filed with the Securities and Exchange Commission on October 13, 2017. Parent is not obligated to make any sales of common stock under the agreement.
On October 26, 2017, Parent entered into an asset purchase agreement pursuant to which it sold legacy intellectual property of its predecessor, Biodel, for $4.5 million.
Optionen
| Boardmail an "t1me" |
Wertpapier: Albireo Pharma |
Optionen
| Boardmail an "crown_odyssey" |
Wertpapier: Albireo Pharma |
und ich auch nicht, macht jetzt richtig Spaß,..
Optionen
| Boardmail an "Uhrzeit" |
Wertpapier: Albireo Pharma |
Optionen
| Boardmail an "Uhrzeit" |
Wertpapier: Albireo Pharma |
Optionen
| Boardmail an "Uhrzeit" |
Wertpapier: Albireo Pharma |
Angehängte Grafik:
albiro.jpg (verkleinert auf 54%)
albiro.jpg (verkleinert auf 54%)
albireo ist nach dem merger mit biodel ein völlig neues unternehmen
Optionen
| Boardmail an "crown_odyssey" |
Wertpapier: Albireo Pharma |
Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
View printer-friendly version
<< Back
PDF Version
BOSTON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 1,970,000 shares of its common stock at a price to the public of $33.00 per share. In addition, the underwriters have exercised an option to purchase an additional 295,500 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $74.8 million and net proceeds of approximately $69.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Cowen and William Blair acted as joint book-running managers and representatives of the underwriters for the offering. Needham & Company, Wedbush PacGrow and Roth Capital Partners acted as co-managers.
The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC). The final prospectus supplement and accompanying prospectus have been filed with the SEC and are available at the SEC’s website located at www.sec.gov, copies of which may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at 631-274-2806, and from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at 1-800-621-0687 or email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate for the treatment of patients with the orphan pediatric liver disease known as progressive familial intrahepatic cholestasis, as well as a Phase 2 product candidate. In addition, Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first IBAT inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com
Source: Albireo Pharma, Inc.
53,5 Mio. zum 31.12.2017
55 Mio. Elobixibat Zulassung
69,9 Mio. Nettoerwerb aus dem jetzigen offering.
Ob aus dem ATM offering über maximal 50 Mio. $ noch was dazukommt werden wir erst mit dem Jahresbericht oder den Q1 Zahlen erfahren. 15 Mio. können noch aus dem Royaltie Agreement im Laufe der nächsten Jahre dazukommen.
11148285
voll verwässert
12257866 (Optionen, Mitarbeiter Programm, ...)
Noch kurz etwas zu Übernahme. Sanofi hat heute Ablynx mit 21% Aufschlag gekauft und vor 1-2 Wochen eine andere Firma mit 67% Aufschlag auf den Börsenkurs. Wäre zwar schnelles Geld, aber ich bin mir nicht sicher ob ich so etwas aktuell toll finden würde. Eher nicht...